FDA APPROVES FIRST TREATMENT FOR NONMETASTATIC, CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Aschenbrenner, Diane S.
机构：
来源：
AMERICAN JOURNAL OF NURSING | 2018年 / 118卷 / 06期
关键词：
D O I：
10.1097/01.NAJ.0000534848.12514.1c
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
引用
收藏
页码：26 / 26
页数：1
相关论文
共 50 条
  • [31] DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES
    Yanev, I
    Aprikian, A.
    Nablsi, E.
    Primiani, J.
    Vaillancourt, Z.
    Dragomir, A.
    VALUE IN HEALTH, 2018, 21 : S73 - S73
  • [32] Does nonmetastatic castration-resistant prostate cancer still exist?
    Celestia S. Higano
    Nature Reviews Clinical Oncology, 2018, 15 : 350 - 351
  • [33] Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan
    Shah, Ruchitbhai
    Botteman, Marc
    Waldeck, Reginald
    FUTURE ONCOLOGY, 2019, 15 (35) : 4069 - 4081
  • [34] Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
    Avxentyev, N. A.
    Frolov, M. Yu
    Makarova, Yu, V
    ONKOUROLOGIYA, 2020, 16 (02): : 82 - 96
  • [35] Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
    Swami, Umang
    Hong, Agnes
    Diessner, Brandon
    Young, Christopher
    Bunner, Scott H.
    Xie, Bin
    Ramaswamy, Krishnan
    Chastek, Benjamin
    El Chaar, Nader
    Gupta, Sumati
    FUTURE ONCOLOGY, 2024, 20 (32) : 2467 - 2480
  • [36] Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    George, Daniel J.
    Morgans, Alicia K.
    Constantinovici, Niculae
    Khan, Nasreen
    Khan, Javeed
    Chen, Guifang
    Hlebec, Vlasta
    Shore, Neal D.
    JAMA NETWORK OPEN, 2024, 7 (08) : e2429783
  • [37] ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 2 - 5
  • [38] PSMA PET–CT redefines nonmetastatic castration-resistant prostate cancer
    Piet Ost
    Nature Reviews Urology, 2020, 17 : 133 - 134
  • [39] Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment
    Srinivas, Sandy
    Mohamed, Ateesha F.
    Appukkuttan, Sreevalsa
    Botteman, Marc
    Ng, Xinyi
    Joshi, Namita
    Tsai, Jui-Hua
    Fang, Jarjieh
    Waldeck, A. Reginald
    Simmons, Stacey J.
    CANCER MEDICINE, 2020, 9 (18): : 6586 - 6596
  • [40] Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
    Feng, Felix Y.
    Thomas, Shibu
    Saad, Fred
    Gormley, Michael
    Yu, Margaret K.
    Ricci, Deborah S.
    Rooney, Brendan
    Brookman-May, Sabine
    McCarthy, Sharon
    Olmos, David
    Chowdhury, Simon
    Hadaschik, Boris
    Liu, Yang
    Davicioni, Elai
    Smith, Matthew R.
    Small, Eric J.
    JAMA ONCOLOGY, 2021, 7 (07) : 1005 - 1014
12345